Cost of hospitalizations due to microvascular and macrovascular complications in type 1 and type 2 diabetic patients in Bulgaria

References

• WHO Media Centre [Internet]. Geneva: World Health Organization; c2015. Diabetes, Fact sheet N°312; January 2015 [cited 2015 Mar 10]; [about 4 screens]. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/
   Google Scholar
• Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, Nichols G. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2011;87(3):293–301.
   Web of Science ®Google Scholar
• Shaw JE, Sicree RA, Zimment PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.
   PubMed Web of Science ®Google Scholar
• Arredondo A. Type 2 diabetes and health care costs in Latin America: exploring the need for greater preventive medicine. BMC Medicine. 2014;12:136. Available from: http://www.biomedcentral.com/1741-7015/12/136
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. Diabetes atlas. 5th ed. Brussels: Taylor & Francis; 2011.
   Google Scholar
• Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005;28(9):2130–2135.
   PubMed Web of Science ®Google Scholar
• Borisova AM, Zaharieva S, Tankova T, Petkova M, Hristov V, Koprivarova K. Preporaki za dobra klinichna praktika pri zaharen diabet [Guidelines on the treatment of diabetes mellitus]. Sofia: Taylor & Francis; 2013. Bulgarian. Available from: http://endo-bg.com/pictures/Preporuki-diabed.pdf
   Google Scholar
• Khan R. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care. 1998;21:296–308.
   PubMed Web of Science ®Google Scholar
• Abrass CK. Diabetic nephropathy: mechanisms of mesangial matrix expansion. West J Med. 1995;162(4):318–321.
   PubMedGoogle Scholar
• McFarlane SI, Farag A, Sowers J. Calcium antagonists in patients with type 2 diabetes and hypertension. Cardiovascular Drug Rev. 2003;21(2):105–118.
   PubMed Web of Science ®Google Scholar
• Pashkunova S, Ivanov V, Savov A. Savremenen pogled v patogenezata na diabetnata nefropatia [Contemporary view of the pathogenesis of diabetic nephropathy]. Vivata [Internet]. 2012 Mar 21 [cited 2015 Jan 20] [about 5 screens]. Available from: http://vivata.bg/diabetic-nephropathy
   Google Scholar
• Whaley-Connel A, Sowers JR. Hypertension and insulin resistance. Hypertension. 2009;54:974–980.
   PubMed Web of Science ®Google Scholar
• Zhang P-Y. Cardiovascular disease in diabetes. Eur Rev Med Pharmacol Sci. 2014;18:2205–2214.
   PubMed Web of Science ®Google Scholar
• Anwer Z, Sharma PK, Garg VK, Kumar N, Kumari A. Hypertension management in diabetic patients. Eur Rev Med Pharmacol Sci. 2011;15:1256–1263.
   PubMed Web of Science ®Google Scholar
• Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther. 2008;88(11):1322–1335.
   PubMed Web of Science ®Google Scholar
• Chibber R, Molinatti PA, Rosatto N, Lambourne B, Kohner EM. Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia. 1997;40(2):156–164.
   PubMed Web of Science ®Google Scholar
• Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical Diabetes. 2008;26(2):77–82.
   Google Scholar
• Czech A, Cypryk K, Czupryniak L, Gajewska D, Grzeszczak W, Gumprecht J, Idzior-Waluś B, Jarosz-Chobot P, Kalarus Z, Karnafel W, Kokoszka A, Koblik T, Korzon-Burakowska A, Kowalska I, Loba J, Majkowska L, Małecki M, Mamcarz A, Mirkiewicz-Sieradzka B, Młynarski W, Noczyńska A, Raczyńska K, Sieradzki J, Słowik A, Solnica B, Stankiewicz A, Szadkowska A, Szelachowska M, Wender-Ożegowska E, Wierusz-Wysocka B, Zozulińska-Ziółkiewicz D. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę, 2014 [Clinical guidelines for the management of patients with diabetes, 2014]. Diabetologia Kliniczna. 2014;3(A):S1–71.( Polish)
   Google Scholar
• Bjegovic V, Terzic Z, Marinkovic J, Latic N, Sipetic S, Laaser U. The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management. Eur J Health Econ. 2007;8:97–103.
   PubMed Web of Science ®Google Scholar
• Gordois A, Shuffham P, Shaerer A, Oglesby A. The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complicat. 2004;18:18–26.
   PubMed Web of Science ®Google Scholar
• Hex N, Bartlet C, Wright D, Taylor M, Varley D. Diabetic Med. 2012;29:855–862.
   PubMed Web of Science ®Google Scholar
• Doneva M, Valov V, Borisova A-M, Tankova T, Savova A, Manova M, Czech M, Petrova G. Comparative analysis of the cost of insulin treated patients in Bulgaria. Biotechnol Biotechnol Equip. 2013;27(2):3748–3752.
   Web of Science ®Google Scholar
• Valov V, Doneva M, Borisova A-M, Tankova T, Czech M, Manova M, Savova A, Peikova L, Petrova G. Regional differences in diabetic patients' pharmacotherapy in Bulgaria. Eur Rev Med Pharmacol Sci. 2014;18:1499–1506.
   PubMed Web of Science ®Google Scholar
• National Health Insurance Fund [Internet]. Sofia: Taylor & Francis; c2009–2015 [cited 2014 Nov 20]. Bulgarian. Available from: www.nhif.bg
   Google Scholar
• National Council on Prices and Reimbursement of Medicinal Products [Internet]. Sofia: NCPRMP. Positive Drug List [cited 2014 Nov 20]. Bulgarian. Available from: www.ncpr.bg
   Google Scholar
• O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther. 2003;25(3):1017–1038.
   PubMed Web of Science ®Google Scholar
• Kanavos P, van den Aardweg S, Schurer W. Diabetes expenditure, burden of disease and management in 5 EU countries. Taylor & Francis [Internet]. 2012 [cited 2015 Jan 20]. Available from: http://www.lse.ac.uk/LSEHealthAndSocialCare/research/LSEHealth/MTRG/LSEDiabetesReport26Jan2012.pdf
   Google Scholar
• Clarke PM, Glasziou P, Patel A, Chalmers J, Woodward M, Harrap SB, Salomon JA. Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis. PLoS Med. 2010;7(2):e1000236.
   PubMed Web of Science ®Google Scholar
• Lesniowska J, Schubert A, Wojna M, Skrzekowska-Baran I, Fedyna M. Costs of diabetes and its complications in Poland. Eur J Heatlh Econ. 2014;15(6):653–660.
   PubMed Web of Science ®Google Scholar
• Domeikiene A, Vaivadaite J, Ivanauskiene R, Padaiga Z. Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania. Medicina. 2014;50(1):54–60.
   PubMed Web of Science ®Google Scholar